peptidylprolyl isomerase A pseudogene 76Genealiases: []
Q-omics provides the consensus-scored PPIAP76 profile across patient tissues and cancer cell-line models. PPIAP76 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PPIAP76 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, PPIAP76 RNA expression shows 7,098 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, COAD, and UVM as cancer lineages where PPIAP76 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP76 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP76 survival associations across molecular data types. PPIAP76 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP76 RNA expression–survival associations across cancer types. High PPIAP76 expression shows unfavorable associations in STAD, UVM, THYM and HNSC, but favorable associations in SKCM and DLBC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for PPIAP76 RNA expression.
This table summarizes PPIAP76 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP76. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP76 shows lower tumor expression in THCA and higher tumor expression in COAD, KIRC, LUAD, LUSC and BRCA. The COAD box plot shows higher PPIAP76 RNA expression in tumor versus normal tissue (log2 FC = +0.200, t-test p = .009).
This table shows molecular features associated with PPIAP76 in patient tissues and cancer cell lines. In patient samples, PPIAP76 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
